EPB-001 / Elpis Biopharma, Luye Group - LARVOL DELTA

Enhancing Anti-Tumor Immune Response and Overcoming Resistance (PEGS 2022) - "We will report the discovery and preclinical studies of EPIM-001, a bispecific IL2/PD-L1 biologics that has demonstrated multiple mechanisms of action and potent anti-tumor activity; EPB-001, a human anti-Siglec15 antibody that reversed immune suppression and inhibited tumor growth. EPIM-001 and EPB-001 could be promising therapeutics for tumors that are non-responding or resistant to immune checkpoint inhibitor treatment."

Immune Modulation • Inflammation • Oncology • IL2 • PD-L1 • SIGLEC15